Vidarabine

Summary

Vidarabine (CHEMBL1090) is an approved small-molecule antineoplastic agent (ATC S01AD06); indicated across 3 conditions including viral infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01AD06 (+1 more)
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 267.24 Da · C10H13N5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1090
Name	Vidarabine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	21704
ChEBI	CHEBI:45327
ATC	S01AD06, J05AB03
Molecular formula	C10H13N5O4
Molecular weight	267.24
InChIKey	OIRDTQYFTABQOQ-UHTZMRCNSA-N

SMILES: C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N

IUPAC name: (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

ChEBI definition: A purine nucleoside in which adenine is attached to arabinofuranose via a β-N9-glycosidic bond.

Pharmacological roles (ChEBI): antineoplastic agent.

Other ChEBI roles (chemical / environmental): bacterial metabolite.

Also known as: ARA-A, Arasena-a, Arabinosyladenine, CI 673, CI-673, NSC-247519, NSC-404241, NSC-757383, Vidarabina, Vidarabine, Vidarabine anhydrous, Vidarabine monohydrate

Patent coverage: 2,463 distinct patent families (7,461 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,191 (83%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Adenosylhomocysteinase, Dipeptidyl peptidase 4, Adenylate cyclase type 5.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DPP4	7.21	IC50	62	nM	CHEMBL_ACT_2994443

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
eye infectious disorder	4	MONDO:0043885	EFO:1001888

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
herpes simplex infectious disease	3	MONDO:0004609	EFO:1002022

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000985	PHASE3	COMPLETED	Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).